Why it matters
The pilot is moving from concept into a multi-product real-world test spanning hypertension and metabolic care, increasing the value of tracking participant selection criteria, outcomes, and operational models.
Decision implication
Monitor whether participant expansion reveals a repeatable regulatory-adoption pathway for technology-enabled chronic care.
Who or what is affected
- FDA
- Cadence Solutions
- Dexcom
- ACCESS organizations
- clinicians
Evidence and sources
E5 — official federal source
P4L distinguishes the sourced event from the interpretation above. Participation, funding, proposed policy, or program inclusion does not by itself establish clinical effectiveness.
What P4L is watching next
- New participant additions
- changes to intended uses
- safety/RWD findings.